Robert Iwaoka
Interventional Cardiology · Charlotte, NCNPI 1144220377
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 101 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $893 and has fallen 97.5% since, to $23 in 2025. That places this record below the midpoint for interventional cardiology clinicians in NC, where the typical reported total is $5,390.
Across 101 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$419
- Edwards Lifesciences$374
- Abbott$290
- Amgen$258
- Novartis$245
- Akcea Therapeutics, Inc.$103
- plus $605 from 13 others
Across 28 payments — averaging $3177.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$88K
- CSL Behring$547
What the payments were for
- Food & beverage$2,294100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 7 | $419 |
| Edwards Lifesciences | 3 | $374 |
| Abbott | 47 | $290 |
| Amgen | 8 | $258 |
| Novartis | 7 | $245 |
| Akcea Therapeutics, Inc. | 1 | $103 |
| Johnson & Johnson | 5 | $99 |
| Amarin Pharma, Inc. | 1 | $93 |
| AstraZeneca | 5 | $81 |
| Cardiovascular Systems Inc. | 4 | $69 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $52 |
| Abiomed | 1 | $40 |
| Medtronic | 2 | $38 |
| Biosense Webster, Inc. | 1 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| Pfizer | 1 | $23 |
| CSL Behring | 1 | $19 |
| Kestra Medical Technology Services, Inc. | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,294 in reported general payments places this provider in the 20th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $35,439 |
| EntrestoSacubitril/Valsartan | 19 | $32,723 |
| Ezetimibe | 98 | $1,666 |
| Atorvastatin Calcium | 122 | $1,218 |
| Metoprolol Succinate | 117 | $1,213 |
| Rosuvastatin Calcium | 112 | $1,121 |
| Losartan Potassium | 60 | $671 |
| Amlodipine Besylate | 72 | $592 |
| Spironolactone | 51 | $494 |
| ClopidogrelClopidogrel Bisulfate | 48 | $466 |
| Carvedilol | 75 | $462 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 36 | $365 |
| Chlorthalidone | 16 | $341 |
| Metoprolol Tartrate | 31 | $276 |
| Lisinopril | 29 | $264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $23 | $35,43946 claims |
| NovartisEntresto | $245 | $32,72319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Charlotte
- Oluseun AlliCharlotte$485K
- Glen FandettiCharlotte$46K
- John PasquiniCharlotte$32K
- Aamer QureshiCharlotte$27K
- Daniel PuCharlotte$23K
- Nyal BorgesCharlotte$18K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
- Ravish SacharRaleigh$1.6M
- Patrick SimpsonPinehurst$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.